Is there a role for PCSK9 inhibition in patients with high Lp(a)?
Video navigation menu
- Lp(a) baseline and Lp(a) reduction by PCSK9i 01:13
- Lp(a) baseline and treatment effect by PCSK9i on CV risk 03:48
- Change in Lp(a) by PCSK9i and effect on CV risk 05:00
- Lp(a) levels and VTE reduction 09:40
- What have we learned from FOURIER and ODYSSEY OUTCOMES? 10:57
- Clinical guidance 12:05
Achieved Lp(a) levels by PCSK9 inhibition and risk of CV events
- A. showed a linear association at all Lp(a) levels in FOURIER
- B. showed a linear association starting at ~30 nmol/L Lp(a) in FOURIER
- C. were associated, but dependent of change in corrected LDL-c in ODYSSEY OUTCOMES
- D. were not associated; baseline Lp(a) levels and CV risk are associated
This presentation by Vera Bittner, MD was part of the EBAC-accredited symposium "Lp(a), a new lipid frontier in CV risk management and target for therapy" held during the virtual ESC Congress 2020
Vera Bittner, MD is professor at the dept. of medicine, division cardiovascular disease at the University of Alabama at Birmingham, AL, USA.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Sanofi and Novartis